Ignite Creation Date:
2024-05-06 @ 7:20 PM
Last Modification Date:
2024-10-26 @ 3:05 PM
Study NCT ID:
NCT05977673
Status:
RECRUITING
Last Update Posted:
2023-11-24
First Post:
2023-07-28
Brief Title:
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
Sponsor:
Organization:
Fondazione Italiana Linfomi - ETS